Full-Life Technologies, a fully integrated global radiotherapeutics company, announced Monday an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on proprietary peptide engineering technology. The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its Radio Technology manufacturing and logistics platforms to advance compounds into clinical development.
Read the full article: Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline //
Source: https://www.prnewswire.com/news-releases/full-life-technologies-to-acquire-focus-x-therapeutics-bolstering-peptide-focused-radiopharmaceutical-pipeline-301687771.html